ReviewCurrent oncology reports2020
Management of Acute Myeloid Leukemia (AML) in Older Patients.
Review in Current oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Intensive Versus Non-Intensive Therapy in Older Patients with Acute Myeloid Leukemia: A Real-World Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Machine learning-guided risk stratification in elderly AML based on genomic, immunophenotypic and therapeutic profiles.BMC geriatrics · 2026Article
- Cytogenetic Profile of Newly Diagnosed Acute Myeloid Leukemia Patients: Insights from a Study at a Tertiary Care Centre in South India.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Triptonide Suppresses AML via PI3K/AKT Signaling: A Network Pharmacology Approach Validated by Molecular Docking and Experimental Studies.Current issues in molecular biology · 2026Article
- Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.Annals of hematology · 2026Article
- Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population.Future oncology (London, England) · 2025Article
- Article
- Acute myeloid leukemia with plasmacytoid dendritic cell proliferation: A case report and literature review.Oncology letters · 2025Article
- Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.HemaSphere · 2025Article
- Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3.Journal of geriatric oncology · 2025Article
- Investigation methylation status of tumor suppressor geneMolecular biology research communications · 2025Article
- Treatment challenges and outcomes of older patients with acute myeloid leukemia from India.Annals of hematology · 2024Article
- Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.Annals of hematology · 2024Article
- Patient-oncologist discussion of treatment decisions: Exploring the role of a patient-centered communication tool for older adults with acute myeloid leukemia and their caregivers.Journal of geriatric oncology · 2024Article
- DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system.Frontiers in pharmacology · 2024Article
- Nanotechnology-assisted combination drug delivery: a progressive approach for the treatment of acute myeloid leukemia.Therapeutic delivery · 2024Review
- Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.Frontiers in oncology · 2024Review
- Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.Drug delivery and translational research · 2023Review
- Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy.Blood advances · 2023Article
- Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewThe acute myeloid leukemia (AML) treatment landscape has rapidly evolved over the past few years. These changes have several implications for the care of older adults (≥ 60 years), who have inferior clinical outcomes. We review decision-making in older adults, focusing on patient- and disease-related factors. We then summarize current treatment options, including multiple recently approved therapies, based on hypothetical clinical scenarios. RECENT
findingsIn lieu of using chronological age to determine fitness, we highlight the importance of standardized fitness assessments using geriatric assessments. Next, we review intensive and lower-intensity treatment options in the upfront setting. We focus on multiple newly approved medications, including venetoclax, midostaurin, CPX-351, gemtuzumab, glasdegib, enasidenib, and ivosidenib, and their specific indications. Lastly, we briefly discuss supportive care of older adults with AML. Outcomes of older adults with AML remain poor; fortunately, there are many new promising treatment options. Personalized treatment plans based on patient- and disease-specific factors are essential to the care of older adults with AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.